Literature DB >> 23943809

Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer.

Oskar Ragnarsson1, Gudmundur Johannsson, Kjell Geterud, Par Lodding, Per Dahlqvist.   

Abstract

Androgen deprivation is a cornerstone in prostate cancer management. We present a 69-year-old man, with a poorly differentiated prostate cancer with skeletal and lymph node metastases. After medical and subsequent surgical castration serum testosterone concentrations remained inappropriately high (4.9 and 4.5 nmol/L; castration range < 0.5). For cancer staging a CT was performed which showed bilateral adrenal enlargement. Endocrine workup revealed elevated levels of adrenal androgens and adrenal precursors. Mutation analysis confirmed a non-classical 21-hydroxylase deficiency, that is, a mild form of congenital adrenal hyperplasia (CAH). To suppress adrenocorticotrophic hormone and the excess adrenal androgen secretion, treatment with hydrocortisone and prednisolone was started with success. Inadequate testosterone suppression after castration due to previously undiagnosed CAH has not previously been reported. Considering the estimated prevalence of 1% in selected populations, non-classical CAH should be considered when testosterone is not adequately suppressed after castration in men with prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23943809      PMCID: PMC3761979          DOI: 10.1136/bcr-2013-010395

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Incomplete testosterone suppression in prostate cancer.

Authors:  E David Crawford; Kyle O Rove
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  High frequency of nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; B Dupont; P Rubinstein; A Piazza; A Kastelan; M I New
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

3.  Androgen deprivation treatment in prostate cancer.

Authors:  Benjamin C Thomas; David E Neal
Journal:  BMJ       Date:  2013-01-08

Review 4.  Testosterone measurement in patients with prostate cancer.

Authors:  Claude C Schulman; Jacques Irani; Juan Morote; Jack A Schalken; Francesco Montorsi; Piotr L Chlosta; Axel Heidenreich
Journal:  Eur Urol       Date:  2010-07       Impact factor: 20.096

Review 5.  Extensive clinical experience: nonclassical 21-hydroxylase deficiency.

Authors:  Maria I New
Journal:  J Clin Endocrinol Metab       Date:  2006-08-15       Impact factor: 5.958

6.  Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group.

Authors: 
Journal:  Br J Urol       Date:  1997-02

7.  Prevalence of nonclassical steroid 21-hydroxylase deficiency based on a morning salivary 17-hydroxyprogesterone screening test: a small sample study.

Authors:  M Zerah; H Ueshiba; E Wood; P W Speiser; C Crawford; T McDonald; J Pareira; D Gruen; M I New
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

8.  The frequency of 21-alpha hydroxylase enzyme deficiency and related sex hormones in Iraqi healthy male subjects versus patients with acne vulgaris.

Authors:  Khalifa E Sharquie; Adil A Noaimi; Basil O Saleh; Zainab N Anbar
Journal:  Saudi Med J       Date:  2009-12       Impact factor: 1.484

9.  Increased prevalence of heterozygous 21-OH germline mutations in patients with adrenal incidentalomas.

Authors:  S M Baumgartner-Parzer; S Pauschenwein; W Waldhäusl; K Pölzler; P Nowotny; H Vierhapper
Journal:  Clin Endocrinol (Oxf)       Date:  2002-06       Impact factor: 3.478

10.  Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members.

Authors:  Maud Bidet; Christine Bellanné-Chantelot; Marie-Béatrice Galand-Portier; Véronique Tardy; Line Billaud; Kathleen Laborde; Christiane Coussieu; Yves Morel; Christelle Vaury; Jean-Louis Golmard; Aurélie Claustre; Etienne Mornet; Zeina Chakhtoura; Irene Mowszowicz; Anne Bachelot; Philippe Touraine; Frédérique Kuttenn
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

View more
  3 in total

1.  Congenital Adrenal Hyperplasia Causing Poor Response to Androgen Deprivation Therapy in Prostate Cancer.

Authors:  Mustafa Kinaan; Oksana Hamidi; Hanford Yau; Kevin D Courtney; Akin Eraslan; Kenneth Simon
Journal:  J Endocr Soc       Date:  2020-10-23

2.  Massive adrenal incidentalomas and late diagnosis of congenital adrenal hyperplasia in prostate cancer.

Authors:  Xin Feng; Gregory Kline
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-10-28

3.  Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway.

Authors:  Jun Chen; Xiao-Yong Hu
Journal:  Oncol Lett       Date:  2018-08-16       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.